Daniel Klevebring
Overview
Explore the profile of Daniel Klevebring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1472
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghoussaini M, Edwards S, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, et al.
Nat Commun
. 2018 Apr;
9:16193.
PMID: 29633761
This corrects the article DOI: 10.1038/ncomms5999.
2.
Mer A, Lindberg J, Nilsson C, Klevebring D, Wang M, Gronberg H, et al.
J Hematol Oncol
. 2018 Apr;
11(1):52.
PMID: 29625580
Background: Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not yet been comprehensively characterized in...
3.
Wang M, Lindberg J, Klevebring D, Nilsson C, Lehmann S, Gronberg H, et al.
J Natl Cancer Inst
. 2018 Mar;
110(10):1094-1101.
PMID: 29506270
Background: Recent progress in sequencing technologies allows us to explore comprehensive genomic and transcriptomic information to improve the current European LeukemiaNet (ELN) system of acute myeloid leukemia (AML). Methods: We...
4.
Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, et al.
Sci Rep
. 2016 Dec;
6:38037.
PMID: 27901097
Sequencing-based breast cancer diagnostics have the potential to replace routine biomarkers and provide molecular characterization that enable personalized precision medicine. Here we investigate the concordance between sequencing-based and routine diagnostic...
5.
Li J, Ivansson E, Klevebring D, Tobin N, Lindstrom L, Holm J, et al.
Clin Cancer Res
. 2016 Sep;
23(10):2584-2592.
PMID: 27587435
Interval breast cancer is of clinical interest, as it exhibits an aggressive phenotype and evades detection by screening mammography. A comprehensive picture of somatic changes that drive tumors to become...
6.
Wyszynski A, Hong C, Lam K, Michailidou K, Lytle C, Yao S, et al.
Hum Mol Genet
. 2016 Jul;
25(17):3863-3876.
PMID: 27402876
Breast cancer is the most diagnosed malignancy and the second leading cause of cancer mortality in females. Previous association studies have identified variants on 2q35 associated with the risk of...
7.
Georgoudaki A, Prokopec K, Boura V, Hellqvist E, Sohn S, Ostling J, et al.
Cell Rep
. 2016 May;
15(9):2000-11.
PMID: 27210762
Tumors are composed of multiple cell types besides the tumor cells themselves, including innate immune cells such as macrophages. Tumor-associated macrophages (TAMs) are a heterogeneous population of myeloid cells present...
8.
Wang M, Klevebring D, Lindberg J, Czene K, Gronberg H, Rantalainen M
Breast Cancer Res
. 2016 May;
18(1):48.
PMID: 27165105
Background: The histologic grade (HG) of breast cancer is an established prognostic factor. The grade is usually reported on a scale ranging from 1 to 3, where grade 3 tumours...
9.
Whitington T, Gao P, Song W, Ross-Adams H, Lamb A, Yang Y, et al.
Nat Genet
. 2016 Mar;
48(4):387-97.
PMID: 26950096
Molecular characterization of genome-wide association study (GWAS) loci can uncover key genes and biological mechanisms underpinning complex traits and diseases. Here we present deep, high-throughput characterization of gene regulatory mechanisms...
10.
Mer A, Klevebring D, Gronberg H, Rantalainen M
Sci Rep
. 2016 Feb;
6:20200.
PMID: 26830453
Sequencing-based molecular characterization of tumors provides information required for individualized cancer treatment. There are well-defined molecular subtypes of breast cancer that provide improved prognostication compared to routine biomarkers. However, molecular...